COVID modRNA vaxx elevates risk of Coronary Artery Disease
A multivariate meta-analysis and systematic review of original studies assessing cardiovascular adverse events experienced after the COVID-19 vaxx (n = 15) most of which had a control group of unvaxxed participants (n = 11) found, in their primary analysis, that a second dose of the COVID-19 vaxx is associated with an over 3x increase in coronary artery disease compared to unvaxxed control groups and baseline rates within the population. A first dose was associated with an over 1.5x increase in coronary artery disease compared to unvaxxed control groups and baseline rates within the population.
An emerging body of evidence also suggests that many victims may have a genetic predisposition for cardiac SAEs induced by modRNA transfections.
A prospective cohort study integrating two cohort datasets to investigate adverse reactions following the first three doses of the BNT162b2 (n = 218) found, through self-administered electronic questionnaires, that a history of moderate or severe systemic reactions significantly increased the risk of similar systemic reactions after subsequent doses (RR: 1.31 [0.99–1.72] for the second dose; 2.18 [1.56–3.06] for the third dose).
An integrative bioinformatics analysis investigating the molecular mechanisms underlying COVID modRNA transfection associated myocarditis by comparing transcriptomic data from patients with fulminant myocarditis, healthy controls and an individual who developed myocarditis following the COVID-19 vaxx (n = 7) found 80 shared differentially expressed genes between the fulminant myocarditis patients and the post vaxx myocarditis patient mainly involved in immune cell-mediated responses and immune dysregulation. Three hub genes (CXCR3, NKG7, GZMH) were central to the pathogenesis of vaxx-associated myocarditis and Transcription factors TBX21 and STAT4 regulate all three hub genes; miRNA hsa-miR-146a-5p targets CXCR3 and NKG7.
A genome-wide association study conducted within a corporate employee cohort in Japan who received a modRNA booster dose, utilizing genomic and self-reported questionnaire data (n = 2,554), identified six genetic loci with genome-wide significant associations for the severity of local adverse reactions, particularly for swelling of lymph nodes. A meta-analysis with prior genome wide association study from first and second doses found 818 variants from 72 loci with genome-wide significant associations for any of 12 symptoms, suggesting shared genetic risk factors between primary and booster vaccinations.